Digestive Diseases and Sciences

, Volume 54, Issue 10, pp 2070–2083 | Cite as

Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats

  • Marko Sever
  • Robert Klicek
  • Bozo Radic
  • Luka Brcic
  • Ivan Zoricic
  • Domagoj Drmic
  • Mihovil Ivica
  • Ivan Barisic
  • Spomenko Ilic
  • Lidija Berkopic
  • Alenka Boban Blagaic
  • Marijana Coric
  • Danijela Kolenc
  • Hrvoje Vrcic
  • Tomislav Anic
  • Sven Seiwerth
  • Predrag SikiricEmail author
Original Article


The gastric pentadecapeptide BPC 157, which was shown to be safe as an antiulcer peptide in trials for inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and fistula in rat. Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus. BPC 157 (10 μg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice). Postoperatively, features of increasingly exhausted presentation were: weight loss appearing immediately regardless of villus height, twofold increase in crypt depth and fourfold increase in muscle thickness within the first week, jejunal and ileal overdilation, and disturbed jejunum/ileum relation. In contrast, constant weight gain above preoperative values was observed immediately with BPC 157 therapy, both perorally and parenterally, and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days. Moreover, rats treated with pentadecapeptide BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength. In conclusion, pentadecapeptide BPC 157 could be helpful to cure short bowel syndrome.


Gastric pentadecapeptide BPC 157 Short bowel syndrome Rats 


  1. 1.
    Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37:768–777.PubMedCrossRefGoogle Scholar
  2. 2.
    Zoricic I, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 beneficially influences the healing of colon-colon anastomoses in rats. In: Mozsik G, Nagy L, Par A, Rainsford KD, eds. Cell injury and Protection in the Gastrointestinal Tract. From Basic Sciences to Clinical Perspectives 1996. Dodrecht, Boston, London: Kluwer Academic; 1997:249–258.Google Scholar
  3. 3.
    Pereira PM, Bines JE. New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome. J Gastroenterol Hepatol. 2006;21:932–940.PubMedCrossRefGoogle Scholar
  4. 4.
    Sukhotnik I, Slijper N, Karry R, et al. Bombesin stimulates enterocyte turnover following massive small bowel resection in a rat. Pediatr Surg Int. 2007;23:397–404.PubMedCrossRefGoogle Scholar
  5. 5.
    Vanderhoof JA, Kollman KA, Griffin S, Adrian TE. Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat. J Pediatr Gastroenterol Nutr. 1997;25:327–331.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhou X, Li YX, Li N, Li JS. Effect of bowel rehabilitative therapy on structural adaptation of remnant small intestine: animal experiment. World J Gastroenterol. 2001;7:66–73.PubMedGoogle Scholar
  7. 7.
    Osowska S, Moinard C, Neveux N, Loı C, Cynober L. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut. 2004;53:1781–1786.PubMedCrossRefGoogle Scholar
  8. 8.
    Eizaguirre I, Aldazabal P, Barrena MJ, et al. Effect of growth hormone, epidermal growth factor, and insulin on bacterial translocation in experimental short bowel syndrome. J Pediatr Surg. 2000;35:692–695.PubMedCrossRefGoogle Scholar
  9. 9.
    Kato Y, Yu D, Schwartz MZ. Enhancement of intestinal adaptation by hepatocyte growth factor. J Pediatr Surg. 1998;33:235–239.PubMedCrossRefGoogle Scholar
  10. 10.
    Fiore NF, Ledniczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg. 1998;33:24–29.PubMedCrossRefGoogle Scholar
  11. 11.
    Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut. 2002;50:428–435.PubMedCrossRefGoogle Scholar
  12. 12.
    Gillingham MB, Dahly EM, Murali SG, Ney DM. IGF-I treatment facilitates transition from parenteral to enteral nutrition in rats with short bowel syndrome. Am J Physiol Regul Integr Comp Physiol. 2003;284:R363–R371.PubMedGoogle Scholar
  13. 13.
    Petersen TI, Kissmeyer-Nielsen P, Flyvbjerg A, Laurberg S, Christensen H. Effect of insulin-like growth factor I (IGF-I) administration on the healing of colonic anastomoses in rats. Int J Colorectal Dis. 1996;11:19–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Christensen H, Oxlund H, Laurberg S. Growth hormone increases the bursting strength of colonic anastomoses. An experimental study in the rat. Int J Colorectal Dis. 1990;5:130–134.PubMedCrossRefGoogle Scholar
  15. 15.
    Seyer-Hansen M, Andreassen TT, Oxlund H. Strength of colonic anastomoses and skin incisional wounds in old rats - influence by diabetes and growth hormone. Growth Horm IGF Res. 1999;9:254–261.PubMedCrossRefGoogle Scholar
  16. 16.
    Sigalet DL, Martin GR. Hormonal therapy for short bowel syndrome. J Pediatr Surg. 2000;35:360–364.PubMedCrossRefGoogle Scholar
  17. 17.
    Sikiric P, Seiwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 aminoacid peptide BPC fragment, on gastric and duodenal lesion induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci. 1994;54:PL63–PL68.PubMedCrossRefGoogle Scholar
  18. 18.
    Sikiric P, Seiwerth S, Grabarevic Z, et al. The influence of a novel pentadecapeptide BPC 157 on NG-nitro-L-arginine methylester and L-arginine effect on stomach mucosal integrity and blood pressure. Eur J Pharmacol. 1997;332:23–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Sikiric P, Seiwerth S, Grabarevic Z, et al. Beneficial effect of novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci. 1996;41:1604–1614.PubMedCrossRefGoogle Scholar
  20. 20.
    Petrovic I, Dobric I, Drvis P, et al. An experimental model of prolonged esophagitis with sphincter failure in rat and therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci. 2006;102:269–277.PubMedCrossRefGoogle Scholar
  21. 21.
    Dobric I, Drvis P, Petrovic I, et al. Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157. J Pharmacol Sci. 2007;104:7–18.PubMedCrossRefGoogle Scholar
  22. 22.
    Sikiric P, Mikus D, Seiwerth S, et al. Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. Dig Dis Sci. 1997;42:1029–1037.PubMedCrossRefGoogle Scholar
  23. 23.
    Sikiric P, Jadrijevic S, Seiwerth S, et al. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J Physiol (Paris). 1999;93:467–477.CrossRefGoogle Scholar
  24. 24.
    Sikiric P, Seiwerth S, Deskovic S, et al. New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Eur J Pharmacol. 1999;364:23–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Sikiric P, Seiwerth S, Grabarevic Z, et al. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J Physiol (Paris). 2001;95:261–270.Google Scholar
  26. 26.
    Sikiric P, Seiwerth S, Aralica G, et al. Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. J Physiol (Paris). 2001;95:283–288.CrossRefGoogle Scholar
  27. 27.
    Xue XC, Wu YJ, Gao MT, Li WG, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032–1036.PubMedGoogle Scholar
  28. 28.
    Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC–15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1994;272:417–422.Google Scholar
  29. 29.
    Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL 14736, Pliva), is effective in the healing of colocutaneous fistulas in rats: the role of NO-system. J Pharm Sci. 2008;108:7–17.Google Scholar
  30. 30.
    Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: stable gastric pentadecapeptide BPC 157, atropine, ranitidine, and omeprazole. Dig Dis Sci. 2008 (in press).Google Scholar
  31. 31.
    Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157’s effect on healing. J Physiol (Paris). 1997;91:173–178.CrossRefGoogle Scholar
  32. 32.
    Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 2001;27:817–827.PubMedCrossRefGoogle Scholar
  33. 33.
    Sikiric P, Seiwerth S, Mise S, et al. Corticosteroids-impairment healing and gastric pentadecapeptide BPC 157 creams in burned mice. Burns. 2003;29:323–334.PubMedGoogle Scholar
  34. 34.
    Seveljevic Jaran D, Cuzic S, Dominis Kramaric M, et al. Accelerated healing of excisional skin wound by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacol Physiol. 2006;19:266–274.PubMedCrossRefGoogle Scholar
  35. 35.
    Xue XC, Wu YJ, Gao MT. Study of the protective effects of pentadecapeptide BPC 157 on wounds in small type pigs. Chin New Drugs J. 2004;12:602–604.Google Scholar
  36. 36.
    Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570:212–221.PubMedCrossRefGoogle Scholar
  37. 37.
    Bilic M, Bumber Z, Blagaic AB, Batelja L, Seiwerth S, Sikiric P. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns. 2005;31:310–315.PubMedCrossRefGoogle Scholar
  38. 38.
    Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24:1109–1117.PubMedCrossRefGoogle Scholar
  39. 39.
    Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38:716–725.Google Scholar
  40. 40.
    Staresinic M, Sebecic B, Jadrijevic S, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthopaed Res. 2003;21:976–983.CrossRefGoogle Scholar
  41. 41.
    Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide BPC 157, on the healing of segmental bone defect in rabbits. A comparison with bone marrow and autologous cortical bone implantation. Bone. 1999;24:195–202.PubMedCrossRefGoogle Scholar
  42. 42.
    Lazić R, Gabrić N, Dekaris I, Bosnar D, Boban-Blagaić A, Sikirić P. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol. 2005;29:321–325.PubMedGoogle Scholar
  43. 43.
    Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24:982–989.PubMedCrossRefGoogle Scholar
  44. 44.
    Veljaca M, Pavic Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut. 2003;51 (Suppl III):A309.Google Scholar
  45. 45.
    Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J, Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology. 2005;128:A584.Google Scholar
  46. 46.
    Urist MR. The first three decades of bone morphogenetic protein. Osteologie. 1996;4:207–233.Google Scholar
  47. 47.
    Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Duel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science. 1987;237:1333–1336.PubMedCrossRefGoogle Scholar
  48. 48.
    Veljaca M, Chan K, Guglietta A. Digestion of h-EGF, h-TGF alpha and BPC–15 in human gastric juice. Gastroenterology. 1995;108:A761.Google Scholar
  49. 49.
    Mise S, Tonkic A, Pesutic V, et al. The presentation and organization of adaptive cytoprotection in the rat stomach, duodenum, and colon. Dedicated to Andre Robert the founder of the concept of cytoprotection and adaptive cytoprotection. Med Sci Monit. 2006;12:BR146–153.Google Scholar
  50. 50.
    Prkacin I, Aralica G, Perovic D, et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol (Paris). 2001;95:295–301.CrossRefGoogle Scholar
  51. 51.
    Sikiric P, Petek M, Rucman R, et al. A new gastric peptide BPC. An overview of stomach – organoprotection hypothesis and beneficial effect of BPC. J Physiol (Paris). 1993;87:313–327.Google Scholar
  52. 52.
    Wood JD. The first Nobel prize for integrated systems physiology: Ivan Petrovich Pavlov, 1904. Physiology. 2004;19:326–330.PubMedCrossRefGoogle Scholar
  53. 53.
    Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL–10, PLD–116, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14:1–8.CrossRefGoogle Scholar
  54. 54.
    Lovric-Bencic M, Sikiric P, Separovic J, et al. Doxorubicine congestive heart failure-increased big-endothelin 1 plasma concentration: reversal by amlodipine, losartan and gastric pentadecapeptide BPC 157 in rat and mouse. J Pharmacol Sci. 2004;95:19–26.PubMedCrossRefGoogle Scholar
  55. 55.
    Sikiric P, Separovic J, Anic T, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol (Paris). 1999;93:479–485.Google Scholar
  56. 56.
    Radeljak S, Seiwerth S, Sikiric P. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Res. 2004;14:A14–A15.CrossRefGoogle Scholar
  57. 57.
    Mozsik G, Sikiric P, Seiwerth S. Pentadecapeptide BPC 157 (PLD116, PL14736, Pliva) influences ATP energy system and antagonizes 0.6M HCl- and 96% ethanol-gastric lesion in rat. Digestion. 2005;73:41.Google Scholar
  58. 58.
    Pawlik WW, Sikiric P, Brzozowski T, et al. Acceleration of ulcer healing by pentadecapeptide BPC 157 in rats. Involvement of endogenous prostaglandinsand gastric secretion. Gastroenterology. 2004;126:A541.Google Scholar
  59. 59.
    Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammagtory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol (Paris). 1997;91:113–122.CrossRefGoogle Scholar
  60. 60.
    Turkovic B, Sikiric P, Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD–116, PL14736, Pliva) induces nitric oxide synthesis. Gastroenterology. 2004;126:287.Google Scholar
  61. 61.
    Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res. 2008;57:205–210.PubMedCrossRefGoogle Scholar
  62. 62.
    Sandor Z, Vincze A, Jadus MR, Brajsa K, Kolega M, Szabo S. The protective effect of newly isolated peptide PL-10 in the iodoacetamide colitis in rats. Gastroenterology. 1997;112:400.Google Scholar
  63. 63.
    Hastings JC, Winkle WV Jr, Barker E, Hines D, Nichols W. Effect of suture materials on healing wounds of the stomach and colon. Surg Gynecol Obstet. 1975;140:701–770.PubMedGoogle Scholar
  64. 64.
    Frank S, Madlener M, Pfeilschifter J, Werner S. Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. J Invest Dermatol. 1998;111:1058–1064.PubMedCrossRefGoogle Scholar
  65. 65.
    Attard JA, Raval MJ, Martin GR, et al. The effects of systemic hypoxia on colon anastomotic healing: an animal model, Dis Colon Rectum. 2005;48 : 1460–1470.Google Scholar
  66. 66.
    Ulland AE, Shearer JD, Coulter C, Caldwell MD. Altered wound arginine metabolism by corticosterone and retinoic acid. J Surg Res. 1997;70:84–88.Google Scholar
  67. 67.
    Camli A, Barlas M, Yagmurlu A. Does L-arginine induce intestinal adaptation by epithelial growth factor? ANZ J Surg. 2005;75:73–75.PubMedCrossRefGoogle Scholar
  68. 68.
    Kato S, Pinto M, Carvajal A, et al. Tissue factor is regulated by epidermal growth factor in normal and malignant human endometrial epithelial cells. Thromb Haemost. 2005;94:444–453.PubMedGoogle Scholar
  69. 69.
    Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost. 2005;93:964–975.PubMedGoogle Scholar
  70. 70.
    Boban Blagaic A, Mirt Dabic M, Blagaic V, Sikiric P. Pentadecapeptide BPC 157 anagonizes rat ethanol gastric lesion and influences VEGF mRNA. Eur J Biochem. 2003;271:247.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Marko Sever
    • 1
  • Robert Klicek
    • 1
  • Bozo Radic
    • 1
  • Luka Brcic
    • 2
  • Ivan Zoricic
    • 1
  • Domagoj Drmic
    • 1
  • Mihovil Ivica
    • 1
  • Ivan Barisic
    • 1
  • Spomenko Ilic
    • 1
  • Lidija Berkopic
    • 1
  • Alenka Boban Blagaic
    • 1
  • Marijana Coric
    • 2
  • Danijela Kolenc
    • 2
  • Hrvoje Vrcic
    • 1
  • Tomislav Anic
    • 1
  • Sven Seiwerth
    • 2
  • Predrag Sikiric
    • 1
    Email author
  1. 1.Department of Pharmacology, Medical SchoolUniversity of ZagrebZagrebCroatia
  2. 2.Department of Pathology, Medical SchoolUniversity of ZagrebZagrebCroatia

Personalised recommendations